enquiries@ta65uk.co.uk _07425604675 We can now take orders by telephone with debit or credit cards, simply call 07425 604 675 and order.

Professor Sam Lingam at 117A Harley Street, London can now prescribe TA65 500 units
_Login

Macular degeneration and TA-65

First Randomized, Double-Blind, Placebo-Controlled Study to Show Improved Macular Function in Humans
This study summarizes the findings on macular function from a randomized, double-blind, placebo-controlled study of TA-65® in subjects with early age-related macular degeneration (AMD). Subjects taking TA-65®(500 Units) significantly improved their macular function over a 12 month period, whereas subjects in the placebo group demonstrated decreased macular function. The findings suggest that TA-65® can improve macular function in a statistically and possibly clinically significant manner.

➢ Study participants: 38 men and women (52-83 years old)
➢ All patients diagnosed with early age-related macular degeneration
➢ Study length: 12 months
➢ First study to show statistically significant (p=0.04) improvement of retinal threshold sensitivity to light in humans taking TA-65®:
The placebo group showed an increase in retinal threshold sensitivity
Placebo Group
Increase in retinal threshold sensitivity to light over 12 months
Threshold sensitivity to light UP 0.7%
(Increased threshold indicates impairment in macular function)

While, the group taking 500 Units of TA-65® per day showed an improved light sensitivity threshold after one year
TA-65' Group
Decrease in retinal threshold sensitivity to light over 12 months
Threshold sensitivity to light Down 7.5%
(Lower threshold indicates improvement in macular function)

➢ Published in Clinical Ophthalmology, a PubMed-indexed and peer-reviewed journal [PMID: 26869760]

Please contact us for the full paper on pdf.

Try TA65 100 unit capsules or 250 unit capsules and quote AMD at checkout for 5% discount on your first order. /shop